Stock Events

Stock Events

Cardiol Therapeutics 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CT9.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech company that develops treatments for cardiovascular diseases, directly competing with Cardiol Therapeutics' focus on heart disease therapies.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops a wide range of medications, including those for cardiovascular health, making it a competitor in the same therapeutic area as Cardiol Therapeutics.
Merck
MRK
Mkt Cap298.84B
Merck produces various cardiovascular drugs, competing in the same market as Cardiol Therapeutics.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a portfolio of medicines for cardiovascular diseases, directly competing with Cardiol Therapeutics in the heart disease treatment space.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb has a strong presence in the cardiovascular drug market, making it a direct competitor to Cardiol Therapeutics.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie, through its acquisition of Allergan, has expanded its portfolio to include treatments for cardiovascular diseases, competing with Cardiol Therapeutics.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, known for its work in antiviral drugs, also focuses on cardiovascular conditions, positioning it as a competitor to Cardiol Therapeutics.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca has a significant portfolio of cardiovascular drugs, making it a direct competitor to Cardiol Therapeutics in the market for heart disease treatments.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson, through its pharmaceutical division Janssen, develops medications for cardiovascular diseases, competing with Cardiol Therapeutics.
Sanofi
SNY
Mkt Cap116.63B
Sanofi has a diversified healthcare portfolio that includes cardiovascular drugs, making it a competitor to Cardiol Therapeutics in the heart disease treatment market.

About

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Show more...
CEO
Mr. David G. Elsley MBA
Employees
18
Country
United States
ISIN
CA14161Y2006

Listings

MU
DE
CT9.MU
STU
DE
CT9.STU
XNAS
US
CRDL
TO
CA
CRDL.TO

0 Comments

Share your thoughts

FAQ

What is Cardiol Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cardiol Therapeutics stocks are traded under the ticker CT9.MU.
How many employees does Cardiol Therapeutics have?▼
As of April 11, 2026, the company has 18 employees.
In which sector is Cardiol Therapeutics located?▼
Cardiol Therapeutics operates in the Health & Wellness sector.
When did Cardiol Therapeutics complete a stock split?▼
Cardiol Therapeutics has not had any recent stock splits.
Where is Cardiol Therapeutics headquartered?▼
Cardiol Therapeutics is headquartered in Oakville, United States.